机构：[1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[3]Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.[4]Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy
Somatic mutations in epidermal growth factor receptor (EGFR) exon 18 are classified as uncommon or rare mutations in non-small cell lung cancer (NSCLC), in this context, other than G719X or E709X exon 18 mutations are even more rare and heterogeneous. In such scenario, first line treatment options are still debated. The aim of this study was to investigate the response of NSCLC patients harboring very rare exon 18 mutations to EGFR tyrosine kinase inhibitors (EGFR-TKIs).This retrospective descriptive study included 105 patients with NSCLC harboring mutations in EGFR exon 18 diagnosed at West China Hospital. The clinical response to EGFR-TKIs was evaluated according to different classifications of mutations in 45 NSCLC patients: 39 harboring G719X or E709X mutations and 6 harboring very rare mutations in EGFR exon 18.Among 105 patients, 84% (88/105) harbored rare mutations in EGFR exon 18, including G719X and E709X mutations. The remaining 16% (17/105) had very rare mutations in EGFR exon 18, including E709_710delinsX and G724S. For the subsequent efficacy analysis of EGFR-TKI in 45 NSCLC patients, patients harboring very rare mutations achieved a favorable disease control rate (DCR) of 100% and had a median progression-free survival (PFS) of 17.2 months, which was not significantly different compared to patients harboring G719X or E709X (P=0.59).EGFR-TKIs showed great efficacy in terms of responses and survival in patients harboring exon 18 EGFR rare mutations. This may justify the use of targeted therapies as a potential treatment strategy for these patients.2024 Translational Lung Cancer Research. All rights reserved.
基金：
This work was supported by the National Natural
Science Foundation of China (Nos. 82072598, 92159302),
1·3·5 project for disciplines of excellence, West China
Hospital, Sichuan University, China (Nos. ZYJC21052,
ZYGD22009), Science and Technology Project of
Sichuan, China (No. 2022ZDZX0018), and Fundamental
Research Funds for the Central Universities of China (No.
SCU2022D025).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|2 区医学
小类|3 区肿瘤学3 区呼吸系统
最新[2023]版：
大类|2 区医学
小类|3 区肿瘤学3 区呼吸系统
第一作者：
第一作者机构：[1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.[2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.[2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China.[*1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Guoxue Alley, Wuhou District, Chengdu 610041, China[*2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Furong Avenue, Wenjiang District, Chengdu 610041, China
推荐引用方式(GB/T 7714)：
Zhang Yuanyuan,Zeng Hao,Qi Chang,et al.Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18[J].Translational Lung Cancer Research.2024,13(4):875-884.doi:10.21037/tlcr-24-113.
APA：
Zhang Yuanyuan,Zeng Hao,Qi Chang,Tan Sihan,Huang Qin...&Li Yalun.(2024).Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18.Translational Lung Cancer Research,13,(4)
MLA：
Zhang Yuanyuan,et al."Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18".Translational Lung Cancer Research 13..4(2024):875-884
